ARLZ: Looking to Capitalize on Successful Launch of Zontivity®

A director sold after exercising options/sold 388,685 shares at 1.435USD and

A director at Aralez Pharmaceuticals Inc sold after exercising options/sold 388,685 shares at 1.435USD and the significance rating of the trade was 90/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restri...

ARLZ: Zontivity to be Officially Launched in June 2017…

PBSV: Steady as she goes

BCLI: KOL Event Gives Overview of the use of NurOwn® in Alzheimer’s Disease; Raising Valuation to $25/Share...

MNOV: FDA Gives OK to Initiate Clinical Trial of MN-166 to Prevent ARDS in COVID- 19 Patients...